Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II-receptor blockers (ARBs) can influence atrial remodeling, and some clinical studies suggest that they may prevent atrial fibrillation.We conducted a large, randomized, prospective, placebo-controlled, multicenter trial to test whether the ARB valsartan could reduce the recurrence of atrial fibrillation. We enrolled patients who were in sinus rhythm but had had either two or more documented episodes of atrial fibrillation in the previous 6 months or successful cardioversion for atrial fibrillation in the previous 2 weeks. To be eligible, patients also had to have underlying cardiovascular disease, diabetes, or left atrial enlargement. Patients were randomly assigned to receive valsartan or placebo. The two primary end points were the time to a first recurrence of atrial fibrillation and the proportion of patients who had more than one recurrence of atrial fibrillation over the course of 1 year.A total of 1442 patients were enrolled in the study. Atrial fibrillation recurred in 371 of the 722 patients (51.4\%) in the valsartan group, as compared with 375 of 720 (52.1\%) in the placebo group (adjusted hazard ratio, 0.97; 96\% confidence interval [CI], 0.83 to 1.14; P=0.73). More than one episode of atrial fibrillation occurred in 194 of 722 patients (26.9\%) in the valsartan group and in 201 of 720 (27.9\%) in the placebo group (adjusted odds ratio, 0.89; 99\% CI, 0.64 to 1.23; P=0.34). The results were similar in all predefined subgroups of patients, including those who were not receiving angiotensin-converting-enzyme inhibitors.Treatment with valsartan was not associated with a reduction in the incidence of recurrent atrial fibrillation. (ClinicalTrials.gov number, NCT00376272.)
Valsartan for prevention of recurrent atrial fibrillation / Disertori M; Latini R; Maggioni AP; Barlera S; Di Pasquale G; Franzosi MG; Lucci D; Staszewsky L; Tognoni G; Disertori M; Latini R; Di Pasquale G; Franzosi MG; Maggioni AP; Staszewsky L; Delise P; Tognoni G; Bertocchi F; Maiocchi G; Geraci E; Correale E; Lombardi F; Mugelli A; Urso R; Scardi S; Fabbri G; Bartolomei B; Barbato G; Carbonieri E; Ciricugno S; Cosmi F; Pratola C; Rossi MG; Sciarra L; Zeni P; Ceseri M; Atzori A; Bambi F; Baviera M; Bianchini F; Fenicia E; Gianfriddo M; Lonardo G; Luise A; Nota R; Orlando ME; Petrolo R; Pierattini C; Pierota V; Ragno A; Serio C; Tafi A; Tellaroli E; Masson S; Latini R; Vago T; Staszewsky L; Gramenzi S; Orso F; Suliman I; Nicolis E; Casola C; Barlera S; Dall'Osso D; Gorini M; Lucci D; Bianchini E; Cabiddu S; Cangioli I; Carnaghi A; Cipressa ML; Cipressa L; Galbiati L; Lorimer A; Priami P; Moccetti T; Rossi MG; Vaghi F; Capello AF; Rossetti G; Viada E; Morena L; Delucchi M; Reynaud SG; Allemano P; Massobrio N; Gavazzi A; Taddei F; Mor DA; Bortolini F; Lorini M; Inama G; Durin O; Pirelli S; Spotti A; Procopio R; Cuzzucrea D; Gentile G; Margonato A; Bassanelli G; Tavazzi L; Buzzi MP; Rordorf R; Gualco A; Opasich C; Gronda E; Genovese L; Mattioli R; Donatelli F; Uriarte JA; Rauhe W; Bertagnolli C; Canestrini S; Stefenelli C; Cioffi G; Disertori M; Zeni P; Giovanelli C; Rigatelli G; Boni S; Pasini A; Sitta N; Sacchetta A; Borgese L; Sciascia R; Targa L; Raviele A; Madalosso M; Bertaglia E; Zoppo FC; Capanna M; Fiorencis R; Baracca E; Rossi R; Carbonieri E; Rossi I; Trappolin R; Morgera T; Barducci E; Baldin MG; Gobbo G; Zardo F; Hrovatin E; Mos L; Vriz O; Sinagra G; Aleksova A; Scardi S; Mazzone C; Fresco C; Rubartelli P; Moroni LA; Camerieri A; Piana M; Mureddu R; Bertoli D; Petacchi R; Pancaldi LG; Gabrieli L; Urbinati S; Pedone C; Di Pasquale G; Di Niro M; Brunelli A; Bosi S; Censi S; Pratola C; Moruzzi P; Pastori P; Modena MG; Malavasi V; Mezzetti M; Melandri F; Zuppiroli A; Fazi A; Testa R; Venturini E; Mazzinghi F; Cosmi F; Cosmi D; Santoro GM; Minneci C; Galli M; Paperini L; Bovenzi FM; Cortigiani L; Cocchieri M; Severini D; Arcuri GM; Bagliani G; Bernardinangeli M; Proietti G; Proietti G; Bocconcelli P; Pierantozzi A; Monti F; Giamundo L; Tancredi P; Rossini E; Bianchi C; Bettiol F; Giovannini E; Fera MS; Santini M; Bianconi L; Boccanelli A; Morosetti P; Volpe M; Facciolo C; Vacri A; Romanazzi F; Napoletano C; Piccioni LL; Candelmo F; De Marco G; Arnese MR; Vetrano A; Prinzi D; De Rosa P; Capuano V; Torre S; D'Onofrio A; Ammendola E; Chiariello M; Filardi PP; Battista R; De Fusco A; Molero U; Iervoglini A; Stefanelli S; Fattore L; Bosco B; Liguori A; Padula G; De Luca I; Sorino M; Colonna P; D'Agostino C; Pierfelice O; Pettinati G; Muscella A; De Lorenzi E; Falco M; Giannattasio C; Baldi N; Clemente MA; D'Alessandro B; Truncellito L; Arabia F; Ciconte VA; Perticone F; Ruberto C; Buffon A; Tomaselli C; De Rosa F; Mazza S; Zampaglione G; Pirozzi AM; Butera A; Levato M; Musacchio D; Polimeni RM; Lacquaniti V; Pulitanò G; Ruggeri A; Provenzano A; Cuccurullo O; Musolino M; Marrari A; Anastasio L; Schiavello M; Comito MG; Gulizia MM; Francese GM; Vasquez L; Coppolino C; Casale A; D'Urso G; Oliva G; Giordano U; Andolina S; Sanfilippo N; Ingrillì F; Accardo S; Grasso S; Buffa L; Serra E.;M. Disertori;R. Latini;S. Barlera;M. G. Franzosi;L. Staszewsky;A. P. Maggioni;D. Lucci;G. D. Pasquale;G. Tognoni. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - ELETTRONICO. - 360:(2009), pp. 1606-1617. [10.1056/NEJMoa0805710]
Valsartan for prevention of recurrent atrial fibrillation.
MUGELLI, ALESSANDRO;
2009
Abstract
Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II-receptor blockers (ARBs) can influence atrial remodeling, and some clinical studies suggest that they may prevent atrial fibrillation.We conducted a large, randomized, prospective, placebo-controlled, multicenter trial to test whether the ARB valsartan could reduce the recurrence of atrial fibrillation. We enrolled patients who were in sinus rhythm but had had either two or more documented episodes of atrial fibrillation in the previous 6 months or successful cardioversion for atrial fibrillation in the previous 2 weeks. To be eligible, patients also had to have underlying cardiovascular disease, diabetes, or left atrial enlargement. Patients were randomly assigned to receive valsartan or placebo. The two primary end points were the time to a first recurrence of atrial fibrillation and the proportion of patients who had more than one recurrence of atrial fibrillation over the course of 1 year.A total of 1442 patients were enrolled in the study. Atrial fibrillation recurred in 371 of the 722 patients (51.4\%) in the valsartan group, as compared with 375 of 720 (52.1\%) in the placebo group (adjusted hazard ratio, 0.97; 96\% confidence interval [CI], 0.83 to 1.14; P=0.73). More than one episode of atrial fibrillation occurred in 194 of 722 patients (26.9\%) in the valsartan group and in 201 of 720 (27.9\%) in the placebo group (adjusted odds ratio, 0.89; 99\% CI, 0.64 to 1.23; P=0.34). The results were similar in all predefined subgroups of patients, including those who were not receiving angiotensin-converting-enzyme inhibitors.Treatment with valsartan was not associated with a reduction in the incidence of recurrent atrial fibrillation. (ClinicalTrials.gov number, NCT00376272.)
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
